Clinical Trials · NCT01184859

Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo

CompletedPhase 2Desmopressin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Ferring Pharmaceuticals
Enrollment
116
Start date
Jul 2010
Locations
36 sites, Japan
Primary endpoint
Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg - Period 1
View Desmopressin compound reference